An unusual no-reflow phenomenon due to neointimal tissue embolization during drug eluting balloon intervention in stent restenosis: A case report.
acute coronary syndrome
no-reflow phenomenon
percutaneous coronary intervention
Journal
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
ISSN: 1522-726X
Titre abrégé: Catheter Cardiovasc Interv
Pays: United States
ID NLM: 100884139
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
revised:
13
06
2023
received:
14
03
2023
accepted:
09
07
2023
medline:
12
9
2023
pubmed:
19
7
2023
entrez:
19
7
2023
Statut:
ppublish
Résumé
Acute coronary syndrome is one of the leading causes of death worldwide. Percutaneous coronary intervention (PCI), along with various devices, have been technically developed to dramatically improve mortality risk in patients with acute myocardial infarction. However, no-reflow phenomenon still remains a problematic complication during a PCI, even in the era of drug eluting stents. There are various hypotheses and mechanisms for no-reflow phenomenon, but none have been confirmed. Treatment for no-reflow phenomenon also depends on various underlying conditions, but have not yet shown effective improvement. We presented a case of no-reflow phenomenon caused by an unusual cause.
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
481-485Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
Epstein AJ, Rathore SS, Volpp KGM, Krumholz HM. Hospital percutaneous coronary intervention volume and patient mortality, 1998 to 2000. JACC. 2004;43(10):1755-1762.
Dangas GD, Claessen BE, Caixeta A, Sanidas EA, Mintz GS, Mehran R. In-stent restenosis in the drug-eluting stent era. JACC. 2010;56(23):1897-1907.
Bouleti C, Mewton N, Germain S. The no-reflow phenomenon: state of the art. Arch Cardiovasc Dis. 2015;108(12):661-674.
Ito H. No-reflow phenomenon and prognosis in patients with acute myocardial infarction. Nat Clin Pract Cardiovasc Med. 2006;3(9):499-506.
Karimianpour A, Maran A. Impervious coronary no-reflow: a case study. Cardiovasc Pharmacol: Open Access. 2017;6:1-4.
Morishima I, Sone T, Mokuno S, et al. Clinical significance of no-reflow phenomenon observed on angiography after successful treatment of acute myocardial infarction with percutaneous transluminal coronary angioplasty. Am Heart J. 1995;130(2):239-243.
Eeckhout E. The coronary no-reflow phenomenon: a review of mechanisms and therapies. Eur Heart J. 2001;22(9):729-739.
Reffelmann T, Kloner RA. The no-reflow phenomenon: a basic mechanism of myocardial ischemia and reperfusion. Basic Res Cardiol. 2006;101(5):359-372.
Rezkalla SH, Kloner RA. Coronary no-reflow phenomenon: from the experimental laboratory to the cardiac catheterization laboratory. Catheter Cardiovasc Interv. 2008;72(7):950-957.
Chalikias G, Tziakas D. Slow coronary flow: pathophysiology, clinical implications, and therapeutic management. Angiology. 2021;72(9):808-818.
Piana RN, Paik GY, Moscucci M, et al. Incidence and treatment of ‘no-reflow’ after percutaneous coronary intervention. Circulation. 1994;89(6):2514-2518.
Kloner RA, King KS, Harrington MG. No-reflow phenomenon in the heart and brain. Ame J Physiol-Heart Circulatory Physiol. 2018;315(3):H550-H562.
Annibali G, Scrocca I, Aranzulla TC, Meliga E, Maiellaro F, Musumeci G. “No-reflow” phenomenon: a contemporary review. J Clin Med. 2022;11(8):2233.
Wang L, Cheng Z, Gu Y, Peng D. Short-term effects of verapamil and diltiazem in the treatment of no reflow phenomenon: a meta-analysis of randomized controlled trials. BioMed Res Int. 2015;2015:1-7.
Iwakura K, Ito H, Okamura A, et al. Nicorandil treatment in patients with acute myocardial infarction: a meta-analysis. Circ J. 2009;73(5):925-931.
Parham WA, Bouhasin A, Ciaramita JP, Khoukaz S, Herrmann SC, Kern MJ. Coronary hyperemic dose responses of intracoronary sodium nitroprusside. Circulation. 2004;109(10):1236-1243.
Ibanez B, James S, Agewall S, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119-177.
Rezkalla SH, Stankowski RV, Hanna J, Kloner RA. Management of no-reflow phenomenon in the catheterization laboratory. JACC: Cardiovasc Interve. 2017;10(3):215-223.
Niccoli G, Scalone G, Lerman A, Crea F. Coronary microvascular obstruction in acute myocardial infarction. Eur Heart J. 2016;37(13):1024-1033.
Meredith I. ENDEAVOR I: 4-month angiographic and IVUS result. Transcatheter Cardiovascular Therapeutic, Washington DC, USA. 2003.
Nabel EG. Cardiovascular disease. N Engl J Med. 2003;349(1):60-72.
Mueller RL, Sanborn TA. The history of interventional cardiology: cardiac catheterization, angioplasty, and related interventions. Am Heart J. 1995;129(1):146-172.
Karthikeyan G, Bhargava B. Prevention of restenosis after coronary angioplasty. Curr Opin Cardiol. 2004;19(5):500-509.
Eisenberg MJ, Konnyu KJ. Review of randomized clinical trials of drug-eluting stents for the prevention of in-stent restenosis. Am J Cardiol. 2006;98(3):375-382.
Park D-W, Hong M-K, Mintz GS, et al. Two-year follow-up of the quantitative angiographic and volumetric intravascular ultrasound analysis after nonpolymeric paclitaxel-eluting stent implantation. JACC. 2006;48(12):2432-2439.
Schwartz R, Chronos N, Virmani R. Preclinical restenosis models and drug-eluting stents: still important, still much to learn. JACC. 2004;44(7):1373-1385.
Park S-J, Shim WH, Ho DS, et al. A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med. 2003;348(16):1537-1545.